

CHAPTER V

PRESENTATION

EVALUATION OF PARASITE LACTATE
DEHYDROGENASE (pLDH) ASSAY
(OPTIMAL-IT) FOR DETECTION OF
MALARIA ON THAI-BURMESE BORDER

SARIKA PATTANASIN
The College of Public Health
Chulalongkorn University

Background

- Malaria is one of major public health problems on the western Thailand
- Tak, Mae Hong Sorn, Kanchanaburi reported 90% of malaria cases in Thailand
- Drug resistant falciparum malaria most occured on the Thailand border region
- Early diagnosis & prompt artemisinin based therapy are effective for malaria control

Background (cont.)

- Malaria symptoms are very non-specific
- Microscopy diagnosis is informative and considered as gold standard
- Reliable microscopy is very difficult to access in remote areas
- Rapid Diagnosis Tests (RDTs) have been introduced a new dimension to diagnosis and treatment

Rapid Diagnosis Tests(RDTs)

- New perspective in the diagnosis of malaria
- Easy and quick to perform
- Do not require extensive training
- False negative associated with low parasitaemia (< 100 parasites/microliter of blood
- Interpretation of a result can be difficult
- Price range US\$ 0.5-3 per test

Rapid Diagnosis Tests(cont.)

- Histidine-rich protein II e.g. ICT Pf/Pv (AMRAD, Australia), Paracheck Pf (Orchid Biomedical Systems, India)
- Only P. falciparum releases HRP- II
- The test gives negative result to *P.vivax*, *P. ovale*, *P. malariae*
- HRP- II persist in blood long after parasites clearance

Rapid Diagnosis Tests(cont.)

- Parasite Lactate Dehydrogenase (pLDH)
 e.g.OptiMAL (Diamed, Switzerland)
- The test can detect *P. falciparum* and *non-P. falciparum*
- More expensive than Paracheck Pf
- After treatment, give negative result more quickly than HRP II assay

Rationale

- Evaluate 2 different rapid tests against microscopy
 - Optimal-IT (pLDH detecting assay)
 for PF and non-PF
 - Paracheck-Pf (HRP-II detecting assay)
 for PF only

Study design and variables

- Cross-sectional descriptive study
- Specific objectives: To assess sensitivity, specificity, NPV, PPV of OptiMAL-IT
- · Independent variables: Parasitaemia level
- Dependent variables: Diagnostic characteritics of OptiMAL-IT

Study Site & Duration

 Ban Mor Ker Thai
 PopPhra district, Tak province, Thailand during June 17 to July 7, 2002



Inclusion & Exclusion Criteria

- Fever & clinically suspected for malaria presenting at the OPD
- Age > 2 years old
- No pregnancy
- Consent to the study



METHOD

- 2 Set of malaria slides (Thick and Thin smear)
- OptiMAL-IT, Paracheck and Hct
- Blinded study
- 1ST M/S: on-site and rechecked blindly at SMRU
- 2nd M/S: stained in Mae Sod and kept for further investigation
- · Treatment based on microscopy results

Results

- Total consented = 271
- Age 2-81 years, mean = 24 years, SD = 14.6
- Male:Female = 1.7:1
- From microscopy,

53% (144/271) were positive

53% (77/144) P. vivax only

35% (50/144) P. falciparum only

5/144 P. malariae only

2/144 *P. ovale* only

9/144 Mixed infection mainly PF+PV

OptiMAL-IT Performance to PF

Global sensitivity 52/59 = 88.1% (95% CI, 77.1-95.1) Global specificity 190/207 = 91.8% (95% CI, 87.2-95.1)

PPV 52/69 = 75.4% (95% CI, 63.6-84.9)

NPV 190/197 = 96.4% (95% CI, 92.8-98.6)

Paracheck Performance to PF

Global sensitivity 53/59 = 89.9% (95% CI, 79.2-96.2) Global specificity 201/210 = 95.7% (95%CI, 92.0-98.0) PPV 53/62 = 85.5% (95%CI, 74.2-93.1) NPV 201/207 = 97.1%(95%CI, 93.8-98.9)

Comparison of OptiMAL-IT & Paracheck to PF Detection

	OptiMAL-IT	Paracheck	p value
Sensitivity	88.1	89.9	0.76
Specificity	91.8	95.7	0.10
PPV	75.4	85.5	0.15
NPV	96.4	97.1	0.71

OptiMAL-IT Performance to non-PF

Global sensitivity 56/86 = 65.1% (95% CI, 54.0-75.1)

Global specificity 178/180 = 98.9% (95% CI=96.0-99.9)

PPV 56/58 = 96.6% (95% CI, 88.1-99.6)

NPV 178/208 = 85.6% (95% CI, 80.1-90.1)

Sensitivity & Parasitaemia

OptiMAL to PF	OptiMAL to non-PF	Parasitaemia /μL	Paracheck to PF
100%	100%	>50,000 n=20	100%
100%	96%	5,000-50,000 n=37	100%
100%	82%	500-5,000 n=37	100%
70%*	64%	100-500, n=21 (*p = 0.58)	90%*
20%	9.5%	< 100,n=26	20%

The study would not have been possible without:

- Dr. Francois Nosten
- Mr. Stephane Proux and SMRU staffs
- 271 patients who consented to the study
- · Diamed Switzerland for giving the tests

